SAN FRANCISCO, Nov. 14 – Myriad Genetics will market its predictive medicine products in Brazil through Sao Paulo-based Fleury Laboratories, the companies announced Wednesday.

The initial products marketed in Brazil from the Salt Lake City-based company will be cancer prediction kits, including ones to detect mutations for types of breast, skin, and colon cancer.

Financial details of the agreement were not disclosed.

Fleury Laboratories has 1,300 employees and 15 clinics throughout Brazil, according to the company.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Under a proposed spending bill, the US National Institutes of Health would see an additional $3 billion in funding.

Robert Redfield, the new pick to lead the US Centers for Disease Control and Prevention, has faced criticism for some of his work.

Researchers from the University of Oxford and the University of Sydney sequenced numerous platypus genomes to study their population history.

In Nature this week: sequenced genomes of five additional Neanderthals, and more.